Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Trastuzumab in HER2-Positive Operable Breast Cancer
NCT01785420Phase 3Terminated
- Start
- May 2013
- Primary completion
- Sep 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of trastuzumab in breast cancer (2 arms). Primary endpoint: Disease Free Survival at 5 years. Started May 2013; status: terminated.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01785420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01785420.